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Trypanosoma brucei protein arginine methyltrans-
ferase 7 (TbPRMT7) exclusively generates mono-
methylarginine (MMA), which directs biological
consequences distinct from that of symmetric dime-
thylarginine (SDMA) and asymmetric dimethylargi-
nine (ADMA). However, determinants controlling the
strict monomethylation activity are unknown. We
present the crystal structure of the TbPRMT7 active
core in complex with S-adenosyl-L-homocysteine
(AdoHcy) and a histone H4 peptide substrate. In the
active site, residues E172, E181, and Q329 hydrogen
bond the guanidino group of the target arginine and
align the terminal guanidino nitrogen in a position
suitable for nucleophilic attack on the methyl group
of S-adenosyl-L-methionine (AdoMet). Structural
comparisons and isothermal titration calorimetry
data suggest that the TbPRMT7 active site is nar-
rower than those of protein arginine dimethyltrans-
ferases, making it unsuitable to bind MMA in a
manner that would support a second turnover, thus
abolishing the production of SDMA and ADMA. Our
results present the structural interpretations for the
monomethylation activity of TbPRMT7.
INTRODUCTION
Arginine methylation is a widespread posttranslational modifica-
tion that plays important roles in transcription regulation, RNA
processing, DNA repair, and signal transduction (Bedford and
Richard, 2005; Bedford and Clarke, 2009; Di Lorenzo and
Bedford, 2011; Yang and Bedford, 2013). Protein arginine
methyltransferases (PRMT) are a family of enzymes that catalyze
the methylation on the guanidino nitrogen atoms of protein
arginyl residues, utilizing S-adenosyl-L-methionine (AdoMet) as
a methyl donor. Based on the kind of methylated arginine
products formed, PRMTs are classified into three types (Fig-
ure 1A). PRMT1, PRMT2, PRMT3, PRMT4/CARM1, PRMT6,756 Structure 22, 756–768, May 6, 2014 ª2014 Elsevier Ltd All rightsand PRMT8 are type I PRMTs that produce monomethylarginine
(MMA) and asymmetric dimethylarginine (ADMA). PRMT5 is a
type II PRMT, producing MMA and symmetric dimethylarginine
(SDMA). Type III PRMTs only form MMA.
Different methylation statuses of arginine residues induce
distinct biological consequences. Asymmetric dimethylarginine
3 in histone H4 (H4R3me2a) is a transcriptional activating mark
(Di Lorenzo and Bedford, 2011), whereas symmetric dimethylar-
ginine 3 in histone H4 (H4R3me2s) is strongly correlated with
suppression of gene expression (Xu et al., 2010). Asymmetric
dimethylation on arginine 2 in histone H3 (H3R2me2a) inhibits
the binding of WDR5 to the H3 tail, thus preventing the trimethy-
lation on histone H3 lysine 4 by the MLL1 complex (Guccione
et al., 2007; Iberg et al., 2008). Conversely, symmetric dimethyla-
tion on arginine 2 in histone H3 (H3R2me2s) greatly potentiates
the recruitment of WDR5 to the H3 tail (Migliori et al., 2012). In
yeast,monomethylarginine 2 in histoneH3 (H3R2me1) correlates
with active transcription, whereas transcriptional silencing roles
are attributed to H3R2me2a (Kirmizis et al., 2009). Although the
importance of different arginine methylation statuses has been
noted, structural understanding of how specific product forma-
tion (MMA, ADMA, or SDMA) is controlled by the PRMTs is still
inadequate. Although the structures of several type I PRMTs
(Zhang et al., 2000; Zhang and Cheng, 2003; Weiss et al., 2000;
Yue et al., 2007; Troffer-Charlier et al., 2007; Cheng et al.,
2011;Wang et al., 2014) and a type II PRMT (Sun et al., 2011; An-
tonysamy et al., 2012; Ho et al., 2013) have been characterized,
the structural characterization for a type III PRMT is still absent.
The functions of PRMT7 in mammalian cells are associated
with small nuclear ribonucleoprotein particle biogenesis (Gon-
salvez et al., 2007), DNA repair (Karkhanis et al., 2012), and the
regulation of MLL4-mediated differentiation (Dhar et al., 2012).
Mammalian PRMT7 is a type III PRMT, which forms only MMA
(Zurita-Lopez et al., 2012; Feng et al., 2013). Bacterial-expressed
human PRMT7 (HsPRMT7) displays very low in vitro activity, and
the presence of a second AdoMet-binding-like domain with
unknown function makes HsPRMT7 a less than optimal model
system for trying to understand the origins of product specificity
of type III PRMTs. TbPRMT7, which is suggested to be the
T. brucei homolog of HsPRMT7, is the first clearly characterized
type III PRMT (Fisk et al., 2009). Most importantly, TbPRMT7
lacks the second AdoMet-binding-like domain and shows robustreserved
Figure 1. TbPRMT7 Displays Robust Type III Activity
(A) Types of arginine methylation. Type I PRMTs generate MMA and ADMA, type II PRMTs catalyze MMA and SDMA formation, and type III PRMTs exclusively
generate MMA.
(B) Mapping the catalytic core of TbPRMT7. Enzyme reaction products from full-length TbPRMT7 and truncated variants were subjected to fluorography.
(C) TbPRMT7 methylates H41–21 but not H4R3me11–21. The axis indicates the reaction times (min), and the ordinate represents the methyl group (mM) transferred
from AdoMet to substrates. Black filled circles and red filled circles indicate the use of H41–21 and H4R3me11–21, respectively.
(D) Western blotting assays demonstrate the type III activity of TbPRMT7. The top panel is the Coomassie blue-stained gel, and the lower panels are the western
blots with anti-H4R3me2a, anti-H4R3me2s, and anti-H4R3me1 antibodies, respectively.
(E) TbPRMT7CORE only produces H4R3me1. Reactions were performed at 37C for 9 hr and then subjected to western blotting according to the Experimental
Procedures.
See also Figure S1.
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Structure of TbPRMT7CORE,AdoHcy,H41–21 Complexin vitro activity (Fisk et al., 2009), providing a tractable system to
study the unique product specificity of the class III arginine
methyltransferases.
To understand the origins for the strict monomethylation activ-
ity of TbPRMT7, we determined the structure of the TbPRMT7
enzymatic core in complex with AdoHcy and H41–21 (the first
21 residues of histone H4). In the active-site pocket, the guani-
dino group of residue R3 of H41–21 is hydrogen bonded by resi-
dues E172, E181, and Q329 of TbPRMT7. These interactions
align the terminal guanidino nitrogen atom of the target arginine
in a position suitable for nucleophilic attack on the methyl groupStructure 22of AdoMet. TbPRMT7 has a narrower active-site pocket than the
type I and type II PRMTs, which both make a dimethylated
product. Furthermore, TbPRMT7 binds H4R3me11–21 (the H4
N-terminal tail monomethylated at residue R3) with an affinity
30-fold lower than that of H41–21. Structural modeling reveals
severe steric clashes between the methyl group on MMA and
the active-site residues of TbPRMT7. Collectively, our data sug-
gest that the active-site pocket of TbPRMT7 is relatively small
and is unsuitable for binding MMA in a manner suitable for a
second round of turnover, which abolishes the ability to produce
dimethylarginine residues., 756–768, May 6, 2014 ª2014 Elsevier Ltd All rights reserved 757
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Structure of TbPRMT7CORE,AdoHcy,H41–21 ComplexRESULTS
TbPRMT7 Displays Robust Type III Activity
TbPRMT7 methylated RBP16 (RNA binding protein 16 from
T. brucei) and bovine histone H4 (Figure 1B, lanes 2 and 7). To
investigate whether TbPRMT7 can methylate the N-terminal
tail of histone H4 in vitro, we performed kinetic assays using
H41–21 and H4R3me11–21 as substrates. TbPRMT7 methylated
H41–21 at a rate of 0.0023 mM/min (with a kcat,app of 0.023/min)
but did not methylate H4R3me11–21 (Figure 1C). These results
confirm that residue R3 of H41–21 is an in vitro target of
TbPRMT7. To further analyze the methylated products on
residue R3, western blotting experiments were carried out
with anti-H4R3me1 (detects MMA), anti-H4R3me2a (detects
ADMA), and anti-H4R3me2s (detects SDMA) antibodies. In the
reaction mixture of TbPRMT7, the amount of H4R3me1 nearly
reached the maximum at 1 hr, but H4R3me2a and H4R3me2s
were not detected, even in a prolonged reaction time of 9 hr
(Figure 1D). For Caenorhabditis elegans PRMT5 (CePRMT5), a
type II PRMT and both H4R3me1 and H4R3me2s were detected
(Figure 1D). Human PRMT1 (HsPRMT1) converted the substrate
into H4R3me2a completely by 20 min, and the amount of
H4R3me2a did not vary thereafter (Figure 1D). Collectively,
these results demonstrate that TbPRMT7 methylates R3 in
H41–21 in vitro and only produces MMA, indicating a type III
activity.
Active Core of TbPRMT7
Although the full-length TbPRMT7 demonstrated robust methyl-
transferase activity, extensive crystallization screens failed. The
canonical PRMT catalytic cores are 310 residues in length
(Bedford and Clarke, 2009), but TbPRMT7 has 390 residues.
Thus, we attributed the crystallization failures to the putative flex-
ible regions flanking the catalytic core of TbPRMT7. According to
the sequence alignment with catalytic cores of other PRMTs,
three truncated mutants (residues 36–390, residues 36–378,
and residues 56–378) were generated. Two mutants (residues
36–390 and residues 36–378) exhibited robust activity toward
RBP16 and bovine histones similar to that of the full-length
enzyme (Figure 1B, lanes 3, 4, 8, and 9), whereas there was no
detectable activity from the third mutant (residues 56–378)
toward either RBP16 or bovine histones (Figure 1B, lanes 5
and 10). These data suggest that the stretch from residue 36
to residue 378 represents a catalytic core of TbPRMT7
(TbPRMT7CORE). Consistent with the activity of the full-length
protein, TbPRMT7CORE also displayed strict monomethylation
activity (Figure 1E and Figure S1 available online).
Overall Structure
TheTbPRMT7COREbinarycomplexwithAdoHcy (TbPRMT7CORE,
AdoHcy) and the ternary complex with AdoHcy and H41–21
(TbPRMT7CORE,AdoHcy,H41–21) were crystallized. The struc-
tures were subsequently refined to resolutions of 1.7 and 2.2 A˚,
respectively (Table 1). TbPRMT7CORE exhibits a canonical PRMT
structure,which iscomposedof anN-terminal extension (residues
36–61, gray), an AdoMet-binding domain (residues 62–203,
purple blue), a b-barrel domain (residues 204–213 and residues
241–375, yellow), and a dimerization arm (residues 214–240,
cyan) (Figures 2A and 2B).758 Structure 22, 756–768, May 6, 2014 ª2014 Elsevier Ltd All rightsThe overall fold of TbPRMT7CORE is similar to the structures of
type I and type II PRMTs (represented by rat PRMT3 (RnPRMT3)
and human PRMT5 (HsPRMT5), respectively), with root-mean-
squared deviation for Ca atoms of 1.5A˚ between TbPRMT7
and PRMT3 or 2.9 A˚ between TbPRMT7 and HsPRMT5. Struc-
tural and sequence alignments also reveal several features of
TbPRMT7 (Figures 2C and 3). In the RnPRMT3 structure, the
YF**Y motif, which is exclusively conserved in type I PRMTs,
forms helix aX, which interacts with the AdoHcy (Zhang et al.,
2000). The corresponding sequence in PRMT5 homologs is
PL**N, which constitutes the L0 loop (Figure 3) and participates
in cofactor recognition (Sun et al., 2011; Antonysamy et al.,
2012). The counterpart in TbPRMT7 is VSLIE (Figure 3), which
folds into an extension of the Y-helix. Intriguingly, an N-terminal
extension, which contains two short helices (aU and aV), pro-
trudes outward from the AdoMet-binding domain and packs
against the b-barrel domain of the opposite molecule (Figures
2B and 2D). The THW loops are strictly conserved in type I
PRMTs, whereas the corresponding sequence in TbPRMT7 is
MQW and folds into helix aK (Figure 2E).
Dimerization
Unlike the ring-like dimers in type I PRMT structures (Zhang
et al., 2000; Zhang and Cheng, 2003; Weiss et al., 2000; Yue
et al., 2007; Troffer-Charlier et al., 2007; Cheng et al., 2011),
TbPRMT7CORE forms abowl-like dimer (Figure 4AandFigure S2).
The dimeric interface, which buries a solvent-accessible surface
area of 3,473 A˚2, can be divided into two regions based on the
structural organization (Figure 4A): in region I, the N-extension
(residues 36–61) of monomer A packs against the N-terminal
ends of sheet b9 and b14, the C-terminal end of sheet b13,
and the loop b12/b13 of monomer B, and in region II, helix aF
and the turn of the dimerization arm of monomer A interact
with the surface of helices aY, aA, aB, and aC of monomer B
(Figure 4A).
In region I, residue F43 of helix aU, residues I47, I51, P52, and
V53 of loop aU/aV make extensive hydrophobic contacts with
residue V242 of loop aG/aH0 and residue H370 of sheet b14 (Fig-
ure 4B). Residue R56 forms a delicate hydrogen bond network
with residues T241 and D338, the main-chain oxygen of residue
T237, the main-chain oxygen of residue Q239, and a water
molecule, which in turn interacts with residue D338 and the
main-chain oxygen of residue P342 (Figure 4B). Residue D48
makes hydrogen bonds to residue R283 and the main-chain
amide of residue G364; residue N50 makes hydrogen bonds
with residue R284 and the main-chain oxygens of residues
R283 and F362. In addition to hydrogen bonds and hydro-
phobic interactions, van der Waals contacts from residues
N50, N361, R56, and P345 also contribute to the stabilization
of the interface region I (Figure 4B). Region I of the dimerization
interface is unlikely formed by crystallization packing, because
it can be seen in the structures of TbPRMT7CORE,AdoHcy and
TbPRMT7CORE,AdoHcy,H41–21, which were crystallized in
different space groups. Furthermore, the N-extensions are not
involved in crystallization packing.
Region II is mainly composed of hydrophobic interactions and
hydrogen bonding interactions between the dimerization arm
and the AdoMet-binding domain. Residues V224, W227, L230,
and L232 of the aE/aG loop and residues H234, M235, andreserved
Table 1. Data Collection and Refinement Statistics
TbPRMT7CORE-SeMet TbPRMT7CORE,AdoHcy TbPRMT7CORE,AdoHcy,H41–21
PDB code 4M37 4M38
Data Collection
Space group C2 C2 P21
Unit cell parameters
a, b, c (A˚) 130.3, 40.9, 90.9 130.6, 40.9, 90.8 66.7, 72.8, 72.1
a, b, g () 90, 131, 90 90, 131, 90 90, 111, 90
Wavelength (A˚) 0.9792 0.9792 0.9793
Resolution limits (A˚) 50.00–2.00 (2.03–2.00) 50.00–1.70 (1.73–1.70) 50.0–2.20 (2.28–2.20)
No. of unique reflections 24,609 39,967 32,471
Completeness (%) 99.4 (99.2) 99.8 (99.9) 98.4 (98.7)
Redundancy 7.2 (7.2) 3.7 (3.7) 3.4 (3.4)
Rmerge (%)
a 14.1 (55.9) 6.5 (46.8) 7.5 (23.9)
Mean I/s(I) 12.8 (4.1) 22.4 (4.4) 18.3 (11.0)
Refinement
Resolution limits(A˚) 50.00–1.70 50.00–2.20
Rwork (%)
b/Rfree (%)
c 14.77/18.25 18.78/23.00
Root mean square deviation for bonds (A˚) 0.008 0.009
Root mean square deviation for angles () 1.217 1.188
Mean B factor (A˚2) 18.67 19.07
No. of nonhydrogen protein atoms 2,692 5,289
No. of water oxygen atoms 246 103
Ramachandran plot (%)
Most favored regions 90.0 91.0
Additional allowed regions 9.3 8.3
Generously allowed regions 0.7 0.7
aRmerge = ShSljIhl  <Ih>j/ShSl<Ih>, where Ihl is the lth observation of reflection h and <Ih>.
bRwork factor = ShjjFobs(h)j  jFcal(h)jj/ShjFobs(h)j, where Fobs(h) and Fcal(h) are the observed and calculated structure factors for reflection h, respectively.
cRfree factor was calculated same as Rwork factor using the 5% reflections, which were selected randomly and omitted from refinement.
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Structure of TbPRMT7CORE,AdoHcy,H41–21 ComplexL238 of helix aG make extensively hydrophobic interactions
against residues T60, L64, I65, Y73, and M76 of helix aY; resi-
dues N82 of helix aZ, L108, L111, and M112 of helix aA; and res-
idues L133 and N137 of helix aB (Figure 4C). The hydrogen
bonding interactions consist of bifurcated hydrogen bonds be-
tween residues N141 and D231 that are also conserved among
other PRMTs, hydrogen bonds between residue N69, the back-
bone oxygen of residue L238, and the backbone nitrogen of
residue D240 and hydrogen bonds from residue Y73 to the
main-chain oxygen of residue M235, from residue N77 to the
main-chain oxygen of residue S222, and from residue R228 to
residue N83 (Figure 4C).
To further investigate the oligomerization state of TbPRMT7 in
solution, we performed small-angle X-ray scattering (SAXS). The
molecular mass of TbPRMT7 determined by SAXS is92.9 kDa.
The molecular mass of TbPRMT7 is 44 kDa, suggesting that
TbPRMT7 exists as a dimer in solution (Figure 4D).
AdoHcy Recognition and Substrate Peptide Binding
The AdoHcy is bound in a deep pocket that is composed of both
the N termini of helices aY, aZ, aA, aC, and aD and the C termini
of strands b1, b2, and b4 and adopts an extended conformation
similar to that of other PRMTs (Figures 5A and 5B). AdoHcyStructure 22recognition can be divided into three parts in accordance to
the moieties of AdoHcy. For the homocysteine moiety, residue
R81 of helix aZ interacts with the carboxyl group of the homocys-
teine, residue E101 of strand b1 and the carbonyl oxygen of res-
idue A104 of b1/aA loop make hydrogen bonds to the amino
group of the homocysteine, and residue M75 of helix aY makes
van der Waals contacts the side chain of homocysteine (Fig-
ure 5B). For the ribose moiety, residue E125 of strand b2
hydrogen bonds the two hydroxyls of the ribose (Figure 5B).
For the adenine moiety, the backbone amide and the hydroxyl
group of residue S154 in b3/b4 loop make hydrogen bonds
with the nitrogen N1 and N6 of the adenine, respectively (Fig-
ure 5B). The nitrogen N6 makes an aromatic hydrogen bond to
the phenol ring of residue Y186 of helix aC (Figure 5B). In addition
to hydrogen bonds, hydrophobic residues I102, M153, and I173
also make van der Waals interactions with the adenine ring
(Figure 5B).
Electron density of the first four residues of the H41–21 peptide
substrate was observed in the TbPRMT7CORE,AdoHcy,H41–21
complex (Figure 5C). H41–21 forms a turn on the surface of the
b-barrel domain of TbPRMT7, and the side chain of residue
R3 inserts into the negatively charged pocket (Figures 5A and
5C). The recognition of backbones of H41–21 is predominantly, 756–768, May 6, 2014 ª2014 Elsevier Ltd All rights reserved 759
Figure 2. Structure of TbPRMT7CORE,
AdoHcy,H41–21
(A) Domain architectures of TbPRMT7 and
HsPRMT7. AdoMet-binding domains, b-barrel
domains, and dimerization arms are colored in
purple blue, yellow, and cyan, respectively.
N-terminal extension of TbPRMT7 is shown in
gray, and the AdoMet-binding-like domain of
HsPRMT7 is shown in green.
(B) Structure of TbPRMT7CORE monomer. The
color codes are same as Figure 2A. TbPRMT7CORE
andH41–21 are shown in cartoons, and the AdoHcy
and R3 of H41–21 are displayed in stick models.
Helices are labeled with letters aA–aZ, and b
strands are labeled with numbers 1–14.
(C) Dimeric structure of TbPRMT7CORE,
AdoHcy,H41–21 complex. The AdoHcy and H41–21
are colored in green and magenta, respectively.
The two TbPRMT7CORE monomers are colored in
blue and gray.
(D) Structural comparison of TbPRMT7,
RnPRMT3, and HsPRMT5. Structures of
TbPRMT7CORE (cyan), RnPRMT3 (Protein Data
Bank [PDB] code 1F3L, yellow), and
HsPRMT5CORE (PDB code 4GQB, magenta) are
superimposed. Significant structural differences
are indicated with black arrows.
(E) An enlarged view of the structural superimpo-
sition.
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Structure of TbPRMT7CORE,AdoHcy,H41–21 Complexaccomplished by hydrogen bonding (Figure 5F). The carboxyl of
residue D70 in helix aY makes hydrogen bonds with the back-
bone amides of residues S1 and G2 of H41–21 (Figures 5D and
5F). T176 makes hydrogen bonds with the backbone carbonyl
and the amide of residue R3 of H41–21 (Figures 5D and 5F). Res-
idue F246 preceding helix aH0 also stabilizes the substrate
through van der Waals interactions with the main-chain atoms
of residue R3 of H41–21 (Figure 5D).
The recognition of the side chain of residue R3 of H41–21 is
mediated by hydrogen bonding, electrostatic attractions, and
van der Waals contacts (Figures 5E and 5F). The backbone
carbonyl group and carboxyl group of residue E172 make
hydrogen bonds with nitrogens Nh1 and Nh2 in residue R3 of
H41–21, respectively. Residue E181 makes a pair of hydrogen
bonds with nitrogens Nh1 and Nd in residue R3 of H4
1–21 (Fig-
ure 5E). Residues E172 and E181, which are strictly conserved
in all known PRMTs, are indispensable for activity of TbPRMT7
(Figure 5G). In addition to the hydrogen bonds from residues
E172 and E181, the side chain of residue Q329 also makes a
hydrogen bond with nitrogen Nh2 of residue R3 in H4
1–21 (Fig-
ure 5E). Residues M75 and F71 bind the side chain of residue
R3 of H41–21 through van der Waals contacts with the target
guanidine and the aliphatic moiety, respectively (Figure 5E).
Hydrogen bonds from residues E172 and E181 appear to
neutralize the positive charge of the guanidino group of residue
R3 of H41–21 and thus enhance its nucleophilicity. These
hydrogen bonds also anchor the terminal nitrogen atom (Nh1 in760 Structure 22, 756–768, May 6, 2014 ª2014 Elsevier Ltd All rights reservedFigure 5E) at an appropriate distance
and orientation for nucleophilic attack
on the methyl group modeled on AdoHcy
(Figure 5E). Consistent with our structuralobservations, mutations on the residues that participate in
substrate recognition abolish or greatly reduce the activity of
TbPRMT7 (Figure 5G).
Transition of Active-Site Pocket from Open to Closed
State
Comparison of the structures of TbPRMT7CORE,AdoHcy,H41–21
and TbPRMT7CORE,AdoHcy revealed the conversion of the
active-site pocket from an open to a closed state upon substrate
binding (Figure 5H and Figure S3). Substrate binding induces a
downward movement of helix aY to cover the target arginine
binding channel (Figures 5H and 5I). The movement of helix aY
allows residue D70 to make hydrogen bonds with backbone am-
idesof residuesS1andG2ofH41–21 andasalt bridgewith residue
K248 of helix H0, which alsomakes a hydrogen bondwith residue
D70main-chain carbonyl (Figure 5I). Upon substrate binding, the
benzene ring of residue F71 rotates120 around the Cb-Cg axis
to pack the aliphatic moiety of residue R3 of H41–21. The carboxyl
group of residue E181 moves inward 2.3A˚ to make a hydrogen
bondwith the guanidino group of residue R3 of H41–21 (Figure 5I).
These rearrangements upon substrate binding create a secluded
active pocket for catalysis (Figure S3).
TbPRMT7 Has a Smaller Target Guanidine Binding
Pocket
A detailed comparison of TbPRMT7, RnPRMT3, and HsPRMT5
active sites uncovered fine structural differences in the target
Figure 3. Sequence Alignment of TbPRMT7,
HsPRMT7,RnPRMT1,RnPRMT3,HsPRMT5,
and CePRMT5
Residues conserved among all the PRMT paralogs
are colored in red, and residues only conserved in
type I, II, or III PRMTs are highlighted with cyan,
green, and yellow, respectively. Residues of
TbPRMT7 participating in substrate binding are
labeled with red stars. Schematic representation
of the secondary structure elements of TbPRMT7
is shown at the top of the sequences. The YF**Y
motifs and THWmotifs in type I PRMTs and the L0
loops in type II PRMTs are labeled.
Structure
Structure of TbPRMT7CORE,AdoHcy,H41–21 Complexguanidine binding pockets (Figures 6A–6D). In TbPRMT7, the
target guanidine is buried in a coin-like pocket via five hydrogen
bonds from two glutamate residues (E172 and E181) and a gluta-
mine residue (Q329) (Figure 6A). Similarly, residues E435 and
E444 in HsPRMT5 also bind the target guanidine (Figure 6B). In
HsPRMT5, residue S669 corresponds to residue Q329 in
TbPRMT7, which has a smaller size, thus creating a unique
cave (cave 1) in the active pocket of HsPRMT5 (Figure 6B).
Residue S669 is strictly conserved in type II PRMTs, and the cor-
responding residues in type I and type III PRMTs are histidine
residues and asparagine residues, respectively (Figure 6E). In
type II and III PRMTs, the residues (X+1 in Figure 6D) following
residues E0 (the first glutamate residues of ‘‘double E’’ motifs
in PRMTs) are leucine or isoleucine residues (Figure 6E) that
adopt upward conformations (Figure 6D), whereas the counter-
parts in type I PRMTs are tryptophan and proline residues (Fig-
ure 6E) that adopt downward conformations, creating unique
caves (cave 2) in the active sites (Figure 6C and Figure S4).
The presence of cave 1 and cave 2 makes the active sites of
type I and II PRMTs larger than that of TbPRMT7 (highlighted
with dotted ovals, Figures 6A–6C). To investigate whether resi-
due Q329 controls the product specificity of TbPRMT7, we
madeQ329H and Q329Smutants and performed in vitro methyl-
ation assays. Unfortunately, the two mutants did not display
dimethylation activities. Similar to wild-type TbPRMT7, mutant
Q329H only produced H4R3me1, whereas mutant Q329 methyl-Structure 22, 756–768, May 6, 2014ated H41–21 with a very weak activity, and
only a trace amount of H4R3me1 was de-
tected (Figure 6F). The enzymatic results
suggest that mutations on Q329 are
insufficient to alter the monomethylation
activity of TbPRMT7.
To further investigate how TbPRMT7
binds MMA, isothermal titration calorim-
etry (ITC) assays were carried out to
determine the affinities of H41–21 and
H4R3me11–21 to TbPRMT7. H41–21 bound
TbPRMT7with aKd of 12 ± 1 mM,whereas
the affinity of H4R3me11–21 to TbPRMT7
(Kd = 395 ± 32 mM) decreased 30-fold
(Figure 6G and Table S1). Collectively,
these data suggest that the target guani-
dine binding pocket of TbPRMT7 is
relatively small and will not support theaddition of a second methyl group to formed MMA because of
steric hindrance and low affinity binding of the MMA substrate.
DISCUSSION
Structural Insights into the Mechanism for Arginine
Methylation by TbPRMT7
The generally accepted catalytic mechanism for PRMTs involves
two strictly conserved glutamates that bind the guanidino group
of the target arginine residue, thus modulating its nucleophilicity
and aligning it to attack the methyl group on AdoMet (Zhang
et al., 2000; Rust et al., 2011). In order to better understand the
involvement of other residues in the active site, the complex of
RnPRMT1,AdoHcy and a substrate peptide (Zhang and Cheng,
2003) has previously been used. However, the RnPRMT1 com-
plex was crystallized at pH 4.6, a pH at which RnPRMT1 is inac-
tive (Zhang and Cheng, 2003), and only the side chain of the
target arginine was sufficiently resolved (Zhang and Cheng,
2003), suggesting that the structure may not represent the active
state of RnPRMT1.
In this study, we present the structure of the TbPRMT7CORE,
AdoHcy,H41–21 ternary complex that was crystallized at pH
6.5. Clear electron density corresponding to the first four resi-
dues of H41–21 was observed. Based on the structures and enzy-
matic results, we provide insight into the catalytic mechanism of
TbPRMT7. In the active site, the target arginine makes hydrogenª2014 Elsevier Ltd All rights reserved 761
Figure 4. TbPRMT7 Forms a Homodimer
(A) A surface representation of a TbPRMT7CORE
dimer with the two monomers shown in pale pink
and gray. The two regions comprising the dimer
interface (I and II) are labeled.
(B) Region I of the dimer interface. The two
monomers are colored as in Figure 4A. Residues
participating in dimerization are shown in stick
model and are labeled. A water molecule is shown
as a red ball. Hydrogen bonds are indicated by
black dashed lines.
(C) Region II of the dimer interface.
(D) TbPRMT7 also forms a homodimer in solution.
The experimental SAXS curve of full-length
TbPRMT7 with data points up to q = 0.6 A˚1
plotted. The top right inset is the PDDF calculated
by GNOM, and the bottom left inset is the DR
model with the crystal structure of TbPRMT7CORE
superimposed onto it. The Rg and Dmax of full-
length TbPRMT7 are 32.8 ± 0.1 and 107.6 A˚,
respectively. DR models were generated using
GASBOR, with final c against the raw SAXS data
of 0.7. The figure was created by VMD (Humphrey
et al., 1996).
See also Figures S2 and S5.
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Structure of TbPRMT7CORE,AdoHcy,H41–21 Complexbonds to residues E172, E181, and Q329 of TbPRMT7.
Hydrogen bonds from residues E172 and E181 would neutralize
the positive charge of the target guanidine and thus enhance its
nucleophilicity. The equivalent glutamate residues in RnPRMT1
(E144 and E153) have been suggested to orient the target guani-
dine of the substrate and modulate its nucleophilicity (Rust et al.,
2011). In TbPRMT7, these hydrogen bonds align the terminal
guanidino nitrogen atom of the residue R3 of H41–21 at a distance
suitable for attacking the methyl group modeled on the AdoHcy
(Figure 5E). Residue E181 could accept a proton from the target
guanidine, in concert with or after the methyl transfer. Interest-
ingly, we observed an outward-inward conformational switch
of E181 upon substrate binding (Figure 5I). Residue Q329
is also important for TbPRMT7 activity, because mutations
Q329S and Q329A completely delete or largely decrease the762 Structure 22, 756–768, May 6, 2014 ª2014 Elsevier Ltd All rights reservedactivity of TbPRMT7 (Figures 5G and
6F). Interestingly, the Q329H variant dis-
plays near wild-type activity (Figure 6F).
Considering the similar sizes of glutamine
and histidine residues, the H329 residue
in Q329H likely makes a hydrogen bond
with the guanidino group of the target
arginine, much the same as Q329 in the
wild-type enzyme.
Enzymatic results also indicated that
the stretch from residue 36 to residue 55
is indispensable for TbPRMT7 activity,
because the truncated variant 56–378
that lacks this stretch (residues 36–55) is
completely inactive (Figure 1B, lanes 5
and 10). Helix aY of TbPRMT7, which
directly interacts with AdoHcy and
H41–21 (Figure 5E), also appears to be
critical for catalysis. The stretch fromresidue 41 to residue 55 packs against helix aY and binds the
b-barrel domain of the opposite TbPRMT7monomer (Figure S5),
which may fix the helix aY in a conformation suitable for AdoMet
recognition and substrate binding.
Structural Determinants of Type III Activity of TbPRMT7
MMA represents a distinct biological signal, not just an interme-
diate of SDMA andADMA formation. For example, H3R2me1and
H3R2me2a in yeast are correlated with active transcription and
transcriptional silencing, respectively (Kirmizis et al., 2009).
TbPRMT7 is the first clearly characterized type III PRMT that
exclusively generates MMA. Our study provides mechanistic in-
sights into the strict monomethylation activity of this type III
PRMT. In the structure of TbPRMT7CORE,AdoHcy,H41–21, the
target guanidine makes five hydrogen bonds to the active-site
Figure 5. AdoHcy Recognition and Sub-
strate Binding in TbPRMT7
(A) An overall view for AdoHcy recognition and
substrate binding. AdoHcy and H41–21 are shown
in stick models. TbPRMT7CORE is shown in elec-
trostatic potential surface, in which positively
charged, negatively charged, and neutral areas
are represented in blue, red, and white, respec-
tively.
(B) AdoHcy recognition. Residues involved in
AdoHcy binding are labeled. Black dashed lines
represent hydrogen bonds. AdoHcy and H41–21
are shown with sticks. The 2Fo  Fc electron
density map was contoured at 3.0 s.
(C) The conformation of the H41–21.
(D) Binding interactions with H41–21.
(E) Binding of the side-chain residue R3 of H41–21.
Residues of TbPRMT7 involved in the binding are
shown and labeled. The hydrogen bonds from the
guanidine group of residue R3 to TbPRMT7 resi-
dues are indicated by dashed lines. The nitrogen
atoms h1, h2, and d of residue R3 are labeled.
(F) Schematic representations of H41–21 (cyan)
binding to TbPRMT7 (gray).
(G) Mutations of residues inTbPRMT7 that partic-
ipate in H41–21 binding abolish or greatly reduce
the activity. Reactions (40 ml) contained 3 mM
H41–21-Trx, 40 mM AdoMet, 1 mM TbPRMT7 or
TbPRMT7 variants in 100 mM Tris (pH 8.0),
100 mM NaCl, 1 mM EDTA, and 5 mM DTT. The
reactions were performed at 37C for 1 hr in trip-
licate. Reactions were subjected to SDS-PAGE
and probed with antibodies as shown.
(H) Comparison of the active sites of
TbPRMT7CORE,AdoHcy,H41–21 (magenta) and
TbPRMT7CORE,AdoHcy (gray). Residues with
substantial conformational changes are shown
and labeled.
(I) An enlarged view of Figure 4H.
See also Figure S3.
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Structure of TbPRMT7CORE,AdoHcy,H41–21 Complexresidues. Addition of a methyl group to the target guanidine will
not only delete a hydrogen bond from the active-site residues,
but also create steric hindrance. Thus, the affinity of
H4R3me11–21 to TbPRMT7 is30-fold lower than that of the un-
methylated counterpart, H41–21.
To further understandMMAbinding by TbPRMT7 froma struc-
tural perspective, we modeled a methyl group onto the target
arginine in four conformations (Figure 7A). In the cases of confor-
mations 1 (Figure 7B) and 2 (Figure 7C), the methyl group seri-Structure 22, 756–768, May 6, 2014ously clashes with residues E172 and
Q329, because the distances from the
modeled methyl to carboxyl oxygen
atom of residue E172 and side chain oxy-
gen of residue Q329 are 1.2 and 1.7 A˚,
respectively (Figures 7B and 7C). In the
case of conformation 3 (Figure 7D), steric
hindrances from the carbonyl and
carboxyl groups of residue E172 to the
methyl group onMMAare generated (Fig-
ure 7D). Because of the steric effects from
the active site, the guanidine group ofMMA will be pushed away from the suitable position for nucleo-
philic attack. If MMA is bound in conformation 4, the hydrogen
bond from residue E181 would be abolished, and steric hin-
drance from residue E181 would be generated (Figure 7E).
Loss of the hydrogen bond from residue E181would result in sig-
nificant attenuation in MMA binding to TbPRMT7 and the nucle-
ophilicity of MMA, which would severely impair the activity
toward MMA. Collectively, our data provide a structural interpre-
tation for the exclusive generation of MMA by TbPRMT7.ª2014 Elsevier Ltd All rights reserved 763
(legend on next page)
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Figure 7. MMA Binding Models for
TbPRMT7
(A) Four putative conformations of MMA in the
TbPRMT7 active site.
(B–F) Models of MMA in the TbPRMT7 active site.
Putative steric hindrances are highlighted with
balls. The distances from the methyl group on
MMA to nearby atoms are measured and labeled.
These models were generated with PyMOL
(DeLano, 2002).
See also Figure S6.
Structure
Structure of TbPRMT7CORE,AdoHcy,H41–21 ComplexThe Structure of TbPRMT7 Provides Implications for
Mammalian PRMT7 Catalytic Specificity
Although the assignment of mammalian PRMT7 as a type III
PRMT has met with controversy in the past, two recent studies
clearly establish that human PRMT7 can only formMMA. Initially,
type III activity was reported by Clarke’s group (Miranda et al.,
2004), whereas a mixture of type I and type II activities was re-
ported by Pestka’s group (Lee et al., 2005). Several following
studies reported that FLAG-PRMT7 purified from mammalian
cells symmetrically dimethylated histone H4R3 (Jelinic et al.,
2006; Karkhanis et al., 2012), H3R2 (Migliori et al., 2012), and
H2AR3 (Karkhanis et al., 2012). It is important to note that the
monoclonal M42 antibody used to purify FLAG-PRMT7 in such
studies also binds endogenous PRMT5 (Nishioka and Reinberg,
2003). Thus, it is reasonable to suppose that the activitiesFigure 6. TbPRMT7 Has a Smaller Target Guanidine Binding Pocket
(A–C) Target guanidine binding pockets of TbPRMT7 (A), RnPRMT3 (B), and HsPRMT5 (C). The upper figures
PRMTs. The hydrogen bonds are indicated with dashed lines. The lower figures highlight the area available f
ovals. Cave 1 in HsPRMT5 and cave 2 in RnPRMT3 are indicated with numbers 1 and 2, respectively.
(D) Superimpositioning of the target guanidine-binding residues of TbPRMT7, RnPRMT3, and HsPRM
Figures 6A–6C.
(E) Sequence alignment of double E loops and THWmotifs. Residues invariant in all enzymes are colored in re
are highlighted with yellow, green, or cyan.
(F) Mutations on residue Q329 are insufficient to alter the type III activity of TbPRMT7. Reactions (40 ml) co
amounts of PRMT proteins (125 nMHsPRMT1, 1 mMCePRMT5 or 1 mMTbPRMT7 ormutants) in 100mMTris (
The reactions were performed at 37C for 3 hr.
(G) Comparison of ITC isotherms for peptides H41–21 (green) and H4R3me11–21 (red) binding to TbPRMT7. T
See also Figure S5 and Table S1.
Structure 22, 756–768, May 6, 2014observed in those studies were influ-
enced by the contamination of endoge-
nous PRMT5. Two recent studies
convincingly demonstrate that bacterial-
expressed human PRMT7 and insect
cell-expressed mouse PRMT7 only cata-
lyze MMA formation on a variety of sub-
strates (Zurita-Lopez et al., 2012; Feng
et al., 2013). Interestingly, mammalian
PRMT7 targets a unique substrate recog-
nition motif in lysine- and arginine-rich
regions, which consists of two arginine
residues separated by one residue (Feng
et al., 2013). Although mammalian
PRMT7 has a second AdoMet-binding
like domain and displays a unique sub-
strate specificity, the active-site residues
of mammalian PRMT7 are identical tothose in TbPRMT7 (M75, E172, E181, and Q329 in TbPRMT7
correspond to M38, E144, E153, and Q309 in human
PRMT7). The conserved active-site residues imply that the
mammalian PRMT7 active-site pocket is similar to that of
TbPRMT7 (Figure S6) and is unsuitable to bind MMA in a confor-
mation that would support a second methylation event. Our
structures reinforce the observation that mammalian PRMT7 is
a type III PRMT.
In summary, our results provide a structural explanation for the
strict monomethylation activity of TbPRMT7 and reinforce the
suggestion that arginine monomethylation is an independent
biological process. Our results further highlight the need to iden-
tify structural modules that can specifically recognize MMA and
the subsequent biological significance of MMA-dependent
interactions.show target guanidine-binding residues of different
or binding of the target guanidine as black dashed
T5. The color codes are the same as those in
d, and residues conserved in type I, II, or III PRMTs
ntained 3 mM H41–21-Trx, 40 mM AdoMet, different
pH 8.0), 100mMNaCl, 1mMEDTA, and 5mMDTT.
he inset lists the measured dissociation constants.
ª2014 Elsevier Ltd All rights reserved 765
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Cloning, Protein Expression and Purification, and Peptide Synthesis
The genes for TbPRMT7 and RBP16 were amplified from the T. brucei cDNA
library and cloned into a modified pET28a (Novagen) vector with a TEV prote-
ase cleavage site after the 63 His tag (pET28-TEV). Genes for HsPRMT1 and
CePRMT5 were subcloned into pET28-TEV vectors. The first 21 residues
(SGRGKGGKGLGKGGAKRHRKV) of histone H4 was fused to the N terminus
of a thioredoxin tag and cloned into the pET28a vector (H41–21-Trx). All variants
were generated by MutanBEST kit (Takara) and verified by DNA sequencing.
All the proteins were expressed in Escherichia coli BL21 (DE3) cells (Novagen)
that were cultured in LB medium at 37C to OD600 = 0.8, then shifted to 16C,
and induced with 0.4 mM isopropyl b-D-thiogalactopyranoside for 24 hr.
These proteins were purified using nickel-chelating resin (QIAGEN) in 30 mM
Tris (pH 8.0), 500 mM NaCl, and then cleaved by TEV protease overnight at
16C to remove the His tag. The nontagged proteins were then purified using
Mono Q and Superdex 200 columns (GE Healthcare). Peptides of H41–21 and
H4R3me11–21 (purity > 95%, verified by mass spectrometry) were synthesized
by GL Biochem or the Keck Institute.
Fluorography
Reactions (40 ml) contained 5 mM RBP16 or 5 mg of bovine thymus histones
(Worthington), 1 mM AdoMet (Sigma), 1 mM [methyl-3H]AdoMet (PerkinElmer),
and 100 nM TbPRMT7 and truncated variants in 100mM Tris (pH 8.0), 100mM
NaCl, 1 mM EDTA, and 5 mM DTT. The reactions were performed at 37C for
2 hr and then subjected to SDS-PAGE, stained with Coomassie blue, and then
subjected to fluorography.
Western Blotting
Reactions (40 ml) contained 3 mMH41–21-Trx, 40 mMAdoMet, different amounts
of PRMT proteins (125 nM HsPRMT1, 1 mM CePRMT5, or 1 mM TbPRMT7 or
variants) in 100 mM Tris (pH 8.0), 100 mM NaCl, 1 mM EDTA, and 5 mM DTT.
The reactions were performed at 37C for indicated times, terminated by the
addition of an equal volume of loading buffer and boiling at 100C for
10 min, and then quadrisected. One portion was subjected to SDS-PAGE
and Coomassie blue stained. The other three samples were subjected to
western blotting using antibodies specific for histone H4 monomethyl R3
(ab17339, Abcam), histone H4 asymmetric dimethyl R3 (39705, Active Motif),
and histone H4 symmetric dimethyl R3 (07-213, Millipore), respectively.
Kinetic Assays
Enzymatic activities toward different peptide substrates were measured with
100 nM TbPRMT7, 1 mM AdoMet, and 1 mM [methyl-3H]AdoMet and initiated
with 200 mM peptide substrates at 37C. Radiolabel incorporation over time
was measured using a highly sensitive discontinuous kinetic assay (Suh-
Lailam and Hevel, 2010). Briefly, 5 ml of the reaction samples were removed
at different time points and quenched by 8Mguanidine HCl, 2.5% trifluoroace-
tic acid solutions and processed with ZipTipsC18 to purify the methylated
peptide from the unreacted radiolabeled AdoMet. Radiolabeled, methylated
peptide products were eluted into scintillation cocktail (Fisher Scientific) and
counted in a liquid scintillation counter.
Small-Angle X-Ray Scattering
SAXS experiments were performed at Argonne National Laboratory. Data
were acquired from three concentrations of full-length TbPRMT7, which
were 1.0, 3.0, and 5.0 mg/ml in the buffer of 30 mM Tris (pH 8.0), 500 mM
NaCl, and 1 mM EDTA, respectively. The data were analyzed in the ATSAS
package (Konarev et al., 2006) following the standard procedures. After sub-
tracting buffer scattering, the data curves from different concentrations were
scaled and merged using PRIMUS (Konarev et al., 2003). GNOM (Semenyuk
and Svergun, 1991) was employed for estimating the particle maximum
dimension (Dmax) and calculating the pair distance distribution function
(PDDF). The radius of gyration Rg of the protein was derived in real space
by using PDDF. The solute molecular mass was evaluated by an online
tool called SAXSMOW (Fischer et al., 2010). Chain-compatible dummy resi-
dues (DR) models were constructed ab initio using the program GASBOR
(Svergun et al., 2001). The solved X-ray structure of TbPRMT7CORE,AdoHcy766 Structure 22, 756–768, May 6, 2014 ª2014 Elsevier Ltd All rightswas superimposed onto the DR model by SUPCOMB (Kozin and Svergun,
2001).
Isothermal Titration Calorimetry
ITC assays were carried out on aMicroCal iTC200 calorimeter (GE Healthcare)
at 25C. The concentrations of TbPRMT7 and HsPRMT1 were determined
spectrophotometrically. A 2-fold excess of AdoHcy (Sigma) was added, and
then the protein concentrations were diluted to 100 mM. The concentrations
of H41–21 and H4R3me11–21 peptides were adjusted to 3 mM. The buffer for
proteins and peptides was 30 mM Tris (pH 8.0), 100 mM NaCl, and 1 mM
EDTA. A reference measurement (peptide injected into the buffer) was carried
out to compensate for the heat of dilution of the peptide. Curve fitting to a
single binding site model was performed by ITC data analysis module of Origin
7.5 (OriginLab) provided by the manufacturer.
Crystallization, Data Collection, and Structure Determination
Native and selenomethionine (SeMet)-derivative TbPRMT7CORE were concen-
trated to 15mg/ml in 10 mM Tris (pH 8.0), 200 mM NaCl, 1 mM EDTA, and
1 mM DTT. The TbPRMT7CORE,AdoHcy complex was prepared by adding
AdoHcy to a concentration of 1 mM, and TbPRMT7CORE,AdoHcy,H41–21
was prepared by adding AdoHcy to 1 mM and H41–21 peptide to 0.7 mM. All
crystals were grown at 293K via the hanging-drop method with the mother
liquor containing 100 mM MES (pH 6.5), 20% PEG 1000. X-ray diffraction
data of the crystal were collected on Beamline 17U1 of the Shanghai Synchro-
tron Radiation Facility (SSRF). The data were processed with HKL2000 and
programs in the CCP4 suite. A single wavelength anomalous scattering data
was collected from aSeMet-derivative TbPRMT7CORE crystal. The initial phase
was calculated using AutoSol in PHENIX, and the initial model was built using
AutoBuild in PHENIX (Adams et al., 2010). The initial model was then
completed through several cycles of manual model rebuilding in COOT (Ems-
ley and Cowtan, 2004) and refinement in REFMAC5 (Murshudov et al., 1997).
The structure of TbPRMT7CORE,AdoHcy,H41–21 was determined bymolecular
replacement with the programMOLREP (Vagin and Teplyakov, 2010) in CCP4i
(Winn et al., 2011). All initial models were refined using themaximum likelihood
method implemented in REFMAC5 (Murshudov et al., 1997) as part of CCP4i
program suite and rebuilt interactively using the program COOT (Emsley and
Cowtan, 2004). During the latter stage, the restrained positional and B-factor
refinement was performed using PHENIX during the refinement. The final
models were evaluated with the programs MOLPROBITY (Davis et al., 2007)
and PROCHECK (Laskowski et al., 1993). Crystallographic parameters are
listed in Table 1. All structure figures were prepared with PyMOL (DeLano,
2002).ACCESSION NUMBERS
The atomic coordinates and structure factors have been deposited in the
Protein Data Bank under accession numbers 4M37 for the TbPRMT7CORE,
AdoHcy complex and 4M38 for the TbPRMT7CORE,AdoHcy,H41–21 complex.SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures and one table and can be found
with this article online at http://dx.doi.org/10.1016/j.str.2014.03.003.
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